<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10</volume><submitter>Rahim Khorasani M</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Ceftolozane/Tazobactam is a β-lactam/β-lactamase inhibitor combination with a high range of efficacy and broad-spectrum action against multidrug-resistant bacterial strains.&lt;h4>Objectives&lt;/h4>The present study aimed to analyze the &lt;i>in vitro&lt;/i> activity of Ceftolozane/Tazobactam against extended-spectrum β-lactamases (ESBLs)-producing &lt;i>Escherichia coli&lt;/i> (ESBLs-EC) and &lt;i>Klebsiella pneumonia&lt;/i> (ESBLs-KP) in the published literature to provide international data on the antimicrobial stewardship programs.&lt;h4>Design&lt;/h4>Systematic review and meta-analysis.&lt;h4>Methods&lt;/h4>A systematic literature search was conducted on the Web of Science, Embase, PubMed, Scopus, and Google Scholar electronic databases from the beginning of databases to December 2022 to cover all pub</pubmed_abstract><journal>Therapeutic advances in infectious disease</journal><pagination>20499361231212074</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10656798</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Global evaluation of the antibacterial activity of Ceftolozane/Tazobactam against ESBLs-producing &lt;i>Escherichia coli&lt;/i> and &lt;i>Klebsiella pneumoniae&lt;/i>: a systematic review and meta-analysis.</pubmed_title><pmcid>PMC10656798</pmcid><pubmed_authors>Rahim Khorasani M</pubmed_authors><pubmed_authors>Rostami S</pubmed_authors><pubmed_authors>Sheikhi R</pubmed_authors><pubmed_authors>Bakhshi A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Global evaluation of the antibacterial activity of Ceftolozane/Tazobactam against ESBLs-producing &lt;i>Escherichia coli&lt;/i> and &lt;i>Klebsiella pneumoniae&lt;/i>: a systematic review and meta-analysis.</name><description>&lt;h4>Background&lt;/h4>Ceftolozane/Tazobactam is a β-lactam/β-lactamase inhibitor combination with a high range of efficacy and broad-spectrum action against multidrug-resistant bacterial strains.&lt;h4>Objectives&lt;/h4>The present study aimed to analyze the &lt;i>in vitro&lt;/i> activity of Ceftolozane/Tazobactam against extended-spectrum β-lactamases (ESBLs)-producing &lt;i>Escherichia coli&lt;/i> (ESBLs-EC) and &lt;i>Klebsiella pneumonia&lt;/i> (ESBLs-KP) in the published literature to provide international data on the antimicrobial stewardship programs.&lt;h4>Design&lt;/h4>Systematic review and meta-analysis.&lt;h4>Methods&lt;/h4>A systematic literature search was conducted on the Web of Science, Embase, PubMed, Scopus, and Google Scholar electronic databases from the beginning of databases to December 2022 to cover all pub</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan-Dec</publication><modification>2025-04-21T18:22:14.205Z</modification><creation>2025-04-05T17:12:08.671Z</creation></dates><accession>S-EPMC10656798</accession><cross_references><pubmed>38029068</pubmed><doi>10.1177/20499361231212074</doi></cross_references></HashMap>